Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

As of now no second Covid-19 booster dose is required, said government sources amid an apparent increase in Covid-19 cases. "First we have to complete the booster drive in the country," said the government sources. India's active caseload currently stands at 2,582, with 134 new cases recorded in the last 24 hours, as per <keyword id="83655" type="General" weightage="80" keywordseo="union-health-ministry" source="Orion">Union Health Ministry</keyword> data. As per ministry data, a total of 220.11 cr vaccine doses (95.13 cr <keyword id="7334317" type="General" weightage="80" keywordseo="second-dose" source="Orion">Second Dose</keyword> and 22.41 cr <keyword id="12813770" type="General" weightage="80" keywordseo="precaution-dose" source="Orion">Precaution Dose</keyword>) have been administered so far under <keyword id="10580665" type="General" weightage="80" keywordseo="nationwide-vaccination-drive" source="Orion">Nationwide Vaccination Drive</keyword>. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/apps/news/series-creators-want-more-money-after-ads-appear-on-netflix/articleshow/96700323.cms">Series creators want more money after ads appear on Netflix</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/thelife/news/pope-benedict-xvi-a-man-at-odds-with-the-modern-world-who-leaves-a-legacy-of-intellectual-brilliance-and-controversy/articleshow/96699003.cms">Pope Benedict XVI: A man at odds with the modern world who leaves a legacy of intellectual brilliance and controversy</a>

No second Covid-19 booster dose required: Govt sources

<ul><li>A new study claims that Covid vaccine protection is short-lived.</li><li><keyword id="44612" type="General" weightage="80" keywordseo="pfizer" source="Orion">Pfizer</keyword> and <keyword id="4912868" type="General" weightage="50" keywordseo="moderna" source="Orion">Moderna</keyword> vaccines offer a longer duration of protection, says a new study.</li><li>In India, <keyword id="2825536" type="General" weightage="20" keywordseo="booster-dose" source="Orion">booster dose</keyword> will be available for free from July 15 till the next 75 days</li></ul>Vaccine protection against Covid-19 is short-lived and, therefore, <keyword id="11223232" type="General" weightage="20" keywordseo="booster-shots" source="Orion">booster shots</keyword> are important, says a new study. "The mRNA vaccines produce the highest levels of antibody response and in our analysis confer more durable protection than other vaccines or exposures," said lead author Jeffrey Townsend from Yale University, in the study, published in the journal Proceedings of the National Academy of Sciences. "However, it is important to remember that natural immunity and vaccination are not mutually exclusive. Many people will have partial immunity from multiple sources, so understanding the relative durability is key to deciding when to provide a boost to your immune system," Townsend added. Since Covid-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts and when it might be necessary for individuals to get an additional booster shot. For the study, the team quantified the likelihood of future infection following natural infection or vaccination by the Moderna, Pfizer, Johnson &amp; Johnson, or Oxford-AstraZeneca vaccines. The risk of breakthrough infections, in which a person becomes infected despite being vaccinated, depends on the vaccine type. According to the study, current mRNA vaccines (Pfizer, Moderna) offer the greatest duration of protection, nearly three times as long as natural infection and the Johnson &amp; Johnson and Oxford-AstraZeneca vaccines. SEE ALSO: <a href="https://www.businessinsider.in/business/news/hdfcs-net-profit-grows-by-19-other-income-grows-by-35/articleshow/92918390.cms">HDFC’s net profit grows by 19%, other income grows by 35%</a> <a href="https://www.businessinsider.in/finance/news/rupee-at-80-heres-how-a-falling-rupee-could-impact-indias-current-account-deficit/articleshow/92897064.cms">Rupee at 80: Here’s how a falling Rupee could impact India's current account deficit</a>

Booster shots important says new study as Covid vaccine protection is short-lived

<ul><li>DCGI has approved market authorisation for the COVID-19 vaccine <keyword id="10678894" type="General" weightage="100" keywordseo="covovax" source="Orion">Covovax</keyword> as a heterologous booster dose for adults.</li><li>The DCGI's approval came following recommendations by the <keyword id="3923779" type="General" weightage="50" keywordseo="subject-expert-committee" source="Orion">Subject Expert Committee</keyword> of the Central Drugs Standard Control Organisation (<keyword id="6375144" type="General" weightage="50" keywordseo="cdsco" source="Orion">CDSCO</keyword>).</li></ul>The <keyword id="6386816" type="General" weightage="50" keywordseo="drug-controller-general-of-india" source="Orion">Drug Controller General of India</keyword> (DCGI ) has approved market authorisation to COVID-19 vaccine Covovax as a heterologous booster dose for adults who have been administered two doses of <keyword id="9617748" type="General" weightage="50" keywordseo="covishield" source="Orion">Covishield</keyword> or <keyword id="9485939" type="General" weightage="50" keywordseo="covaxin" source="Orion">Covaxin</keyword>, official sources said on Monday. The DCGI's approval came following recommendation by the Subject Expert Committee of the Central Drugs Standard Control Organisation (CDSCO). Prakash Kumar Singh, Director of Government and Regulatory Affairs at the <keyword id="95879" type="General" weightage="50" keywordseo="serum-institute-of-india" source="Orion">Serum Institute of India</keyword> (<keyword id="52604" type="General" weightage="80" keywordseo="sii" source="Orion">SII</keyword>), had recently written to the DCGI for the approval of Covovax heterologous booster dose for those aged 18 years and above in view of escalating COVID-19 pandemic situation in some countries, an official source had said. "The Subject Expert Committee of the CDSCO on Wednesday deliberated on the issue and had recommended for market authorisation of Covid jab Covovax as a heterologous booster dose for adults who have been administered two doses of Covishield or Covaxin," an official source said. The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28, 2021, in the 12-17 age group on March 9, 2022, and in children aged 7- 11 years on June 28 last year subject to certain conditions. Covovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. It was granted emergency-use listing by the <keyword id="43588" type="General" weightage="50" keywordseo="world-health-organization" source="Orion">World Health Organization</keyword> (WHO) on December 17, 2021. In August 2020, US-based vaccine maker Novavax Inc. had announced a licence agreement with the SII for the development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate in <keyword id="3658" type="General" weightage="50" keywordseo="india" source="Orion">India</keyword> and low-and-middle-income countries. SEE ALSO: <a href="https://www.businessinsider.in/tech/news/amazon-great-republic-day-sale-2023-best-deals-and-offers-on-tvs/articleshow/96987966.cms">Amazon Great Republic Day Sale 2023 – Best deals and offers on TVs</a> <a href="https://www.businessinsider.in/tech/apps/news/these-audio-setting-tweaks-can-make-music-sound-better-on-spotify/articleshow/96876010.cms">These audio setting tweaks can make music sound better on Spotify</a>

Serum Institute's Covovax gets DCGI approval as a heterologous booster dose

Top <keyword id="12660759" type="General" weightage="20" keywordseo="Indian-genome-scientists" source="Orion">Indian genome scientists</keyword> have recommended a booster dose of COVID-19 vaccines for those above 40 years with preference to high-risk and high-exposure population. The recommendation was made in the weekly bulletin of the Indian SARS-CoV-2 Genomics Sequencing Consortium (<keyword id="10505450" type="General" weightage="50" keywordseo="insacog" source="Orion">INSACOG</keyword>), a network of national testing labs set up by the government to monitor genomic variations of COVID-19. "Vaccination of all remaining unvaccinated at-risk people and consideration of a booster dose for those 40 years of age and over, first targeting the most high-risk / high-exposure may be considered," the INSACOG bulletin said. The recommendation came amid demands for a booster dose of covid vaccines by lawmakers during a discussion in the Lok Sabha on the pandemic situation in the country. Thr INSACOG said genomic surveillance will be critical for early detection of the presence of this variant, to enable necessary public health measures. It also recommended monitoring travel to and from the known affected areas, and contact tracing of COVID-19 cases with an epidemiological link to the affected areas has been implemented along with increased testing. "Vaccination of all remaining unvaccinated at-risk people and consideration of a booster dose for those 40 years of age and over, first targeting the most high-risk / high-exposure may be considered, since low levels of neutralising antibodies from current vaccines are unlikely to be sufficient to neutralise <keyword id="1609796" type="General" weightage="20" keywordseo="omicron" source="Orion">Omicron</keyword>, although risk of severe disease is still likely to be reduced," it said. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/stock-market/news/poor-demand-for-star-healths-ipo-forces-investment-bankers-to-cut-down-on-promoter-offerings/articleshow/88065207.cms">Poor demand for Star Health’s IPO forces investment bankers to cut down on promoter offerings; GMP at ₹10 discount</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/space/news/nasa-grants-415-6-million-to-build-three-commercial-space-stations-in-low-earth-orbit/articleshow/88067097.cms">NASA grants $415.6 million to Jeff Bezos’ Blue Origins and more companies to build commercial space stations</a>

Indian genome scientists recommend COVID-19 booster dose for those above 40 years of age

The ideal time for a <keyword id="2825536" type="General" weightage="20" keywordseo="booster-dose" source="Orion">booster dose</keyword> for COVID-19 vaccine is six months after the second dose, <keyword id="10494595" type="General" weightage="20" keywordseo="Bharat-Biotech-Chairman" source="Orion">Bharat Biotech Chairman</keyword> and Managing Director Krishna Ella said on Wednesday, and also emphasised the importance of having a nasal vaccine. He also pointed out that his company was the first in the world to develop a <keyword id="3225534" type="General" weightage="20" keywordseo="Zika-vaccine" source="Orion">Zika vaccine</keyword>. Taking the <keyword id="9485939" type="General" weightage="50" keywordseo="covaxin" source="Orion">Covaxin</keyword> vaccine by the Prime Minister Narendra Modi showed confidence in Indian Science, he said at the Times Now Summit 2021. "The ideal time for a booster dose is six months after the second dose," Ella stated. <keyword id="149108" type="General" weightage="100" keywordseo="bharat-biotech" source="Orion">Bharat Biotech</keyword> is also looking at nasal vaccine as a booster dose as its scaling up capacity is very easy when compared with Covaxin, he added. About the importance of nasal vaccine, he said the entire world is looking at nasal vaccines. That is the only way to stop transmission. Everyone is trying to figure out the immunology and fortunately, Bharat Biotech has figured it out. "We are coming out with a nasal vaccine, we are thinking that Covaxin can be given as first dose, the second dose can be given a nasal, that is also strategically, scientifically very important because with the second dose, if it is a nasal one, you stop the transmission of the virus...," Ella said. Nasal vaccine works well if someone has been infected or if someone has been vaccinated with one dose, he added. About the PM taking the Covaxin shot, he said, "What would a scientist like to have? A country head taking his vaccine. That is the best satisfaction a scientist can get... It shows confidence in the Indian science, confidence in the startup, and confidence in our innovation...". Speaking about a vaccine for Zika, Ella said Bharat Biotech is ready with a vaccine for Zika virus. Phase I is complete. The government has to take up more trials because there are more cases now. "We were the first company in the world to develop the Zika vaccine in 2014... We were the first one to file for a global patent for Zika vaccine", he added. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/tech/mobile/news/heres-how-you-can-protect-your-smartphone-from-exploding/slidelist/87625685.cms">Here’s how you can protect your smartphone from exploding</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/union-cabinet-approves-declaration-of-november-15-as-janjatiya-gaurav-diwas/articleshow/87629229.cms">Union Cabinet approves declaration of November 15 as Janjatiya Gaurav Diwas</a>

Ideal time for COVID-19 booster shot is six months after the second dose, says Bharat Biotech MD

<ul class="summary-list"><li>The FDA authorized an updated COVID-19 booster tailored to protect against the Omicron variant. </li><li>The CDC recommended the shots, which means they can be shipped across the country.</li></ul>Following the Food and Drug Administration's approval of the newest COVID-19 booster shot, the CDC has now recommended the vaccine — meaning it will be available to millions of Americans later this week.The FDA <a href="https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating" target="_blank" rel="noopener">said in a press release on Monday</a> that the boosters from Moderna and Pfizer-BioNTech help protect against commonly circulating variants, including EG.5 and BA.2.86.The quick-spreading strain EG.5, also known as Eris, has likely been the culprit behind <a href="https://www.insider.com/august-flu-vs-covid-infection-rate-2023-8">recent summer COVID surges</a>, though it doesn't appear to make people any sicker than previous strains, <a href="https://www.insider.com/new-covid-variant-eris-symptoms-transmission-2023-8">Insider previously reported</a>. On Tuesday, the CDC's Advisory Committee backed the FDA's recommendation that individuals over 6 months old get the new vaccine. The CDC's director Dr. Mandy Cohen formally recommend it Tuesday evening, per a statement from the CDC."We have more tools than ever to prevent the worst outcomes from COVID-19," Cohen said in a statement. "CDC is now recommending updated COVID-19 vaccination for everyone 6 months and older to better protect you and your loved ones."    <h2>When will the booster be available?</h2>Since Cohen gave the booster the go-ahead, millions of doses will be shipped within days and could be available at pharmacies and doctors' offices across the country as soon as the end of this week, <a href="https://www.nytimes.com/2023/09/11/health/covid-vaccine-boosters-fda-pfizer-moderna.html" target="_blank" rel="noopener">The New York Times reported. </a>The CDC announced that many people will still be able to get the updated vaccine for free. "For people with health insurance, most plans will cover COVID-19 vaccine at no cost to you," the CDC wrote in a statement. "People who don't have health insurance or with health plans that do not cover the cost can get a free vaccine from their local health centers; state, local, tribal, or territorial health department; and pharmacies participating in the CDC's Bridge Access Program. Children eligible for the Vaccines for Children program also may receive the vaccine from a provider enrolled in that program."The FDA granted approval for people 12 and older to receive a single dose of the latest mRNA vaccine and authorized emergency use for kids 6 months to 11 years of age. Kids aged 6 months to 4 years who have not yet received any vaccination can get three doses of the Pfizer-BioNTech booster or two doses of the Moderna booster, the agency said. "Vaccination remains critical to public health and continued protection against serious consequences of COVID-19, including hospitalization and death," Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said in the agency's press release."The public can be assured that these updated vaccines have met the agency's rigorous scientific standards for safety, effectiveness, and manufacturing quality," Marks added. "We very much encourage those who are eligible to consider getting vaccinated."

The new COVID-19 booster will be available at your local pharmacy by the end of the week

<ul class="summary-list"><li>Four <keyword id="11894310" type="UNKNOWN" weightage="60" keywordseo="vaccine" source="Orion">vaccine</keyword> shots didn't stop people from catching Omicron, an official from an Israeli trial said.</li><li>The trial compared people with a fourth dose to those with three, and found little difference.</li></ul>A landmark Israeli trial is expected to show that four shots of vaccine didn't stop infection by the Omicron variant, according to a study official.While the extra dose — of either Pfizer of Moderna vaccine — seemed to have some effect, rates of infection in the study were not substantially different to those who had three doses of Pfizer, the study official said.Gili Regev-Yochay, a lead investigator on the study, told reporters that "the vaccine is excellent against the Alpha and Delta," but the study found that "for Omicron, it's not good enough," <a href="https://www.timesofisrael.com/israeli-trial-worlds-first-finds-4th-dose-not-good-enough-against-omicron/">The Times of Israel reported Monday evening.</a>The investigator did not release data from the trial, noting that the results are preliminary. But she said she shared the early findings as there was a large public interest, per The Times of <keyword id="6355882" type="UNKNOWN" weightage="60" keywordseo="israel" source="Orion">Israel</keyword>. The findings, if confirmed and vetted by other scientists after publication, could bolster calls for the development of a <a href="https://www.scientificamerican.com/article/whats-holding-up-new-omicron-vaccines1/">new version of the COVID-19 vaccines</a>. Some new types of vaccines <a href="https://www.businessinsider.com/biontech-omicron-variant-coronavirus-covid-19-vaccine-start-work-pfizer-2021-11">are already</a> in the <a href="https://www.businessinsider.com/us-army-universal-vaccine-target-spfn-variants-pan-coronavirus-sars-2021-12">early stages of development</a>.The Israeli trial, launched by the Sheba Medical Center a month ago, is investigating the effect of the Pfizer <keyword id="11946931" type="UNKNOWN" weightage="60" keywordseo="booster" source="Orion">booster</keyword> in 154 people and the Moderna booster in 120 people, <a href="https://www.reuters.com/world/middle-east/israeli-study-shows-4th-shot-covid-19-vaccine-not-able-block-omicron-2022-01-17/">per Reuters</a>. It found that there was an "increase in antibodies" among those who got the fourth shot.But Regev-Yochay said: "we see many infected with Omicron who received the fourth dose. Granted, a bit less than in the control group, but still a lot of infections," per the Times of Israel.The control group were people who had three doses of the Pfizer vaccine.About 500,000 fourth shots of vaccine had been administered in Israel as of Sunday, per the Times of Israel. Vaccines are still protective against severe disease and hospitalization.Figures from the UK health security agency <a href="https://www.businessinsider.com/omicron-chart-protection-2-3-vaccine-booster-effectiveness-hospitalization-symptomatic-2022-1">published December 31</a> found that two doses of vaccine reduced the risk of hospitalization by 72% within 24 weeks of the second shot.That protection waned over time, but a third shot boosted it back up, reducing the risk of hospitalization by 88% for at least two weeks.Scientists hoped that heightened levels of antibodies after a booster shot, which were also <a href="https://www.businessinsider.com/omicron-variant-pfizer-says-3-shots-work-2-less-effective-2021-12">seen after the third shot</a>, could mean that the body would be able to <a href="https://www.businessinsider.com/omicron-vaccines-t-cells-despite-low-antibody-response-2021-12">ward off infection and transmission from Omicron</a>. But lab studies have found that the Omicron variant is <a href="https://www.businessinsider.com/early-research-shows-omicrons-impact-on-covid-19-shots-2021-12">very adept at dodging antibodies</a>, which had been able to block previous variants of the <keyword id="11893194" type="UNKNOWN" weightage="60" keywordseo="coronavirus" source="Orion">coronavirus</keyword>. "We know by now that the level of antibodies needed to protect and not to get infected from Omicron is probably too high for the vaccine, even if it's a good vaccine," said Regev-Yochay, per ReutersIsrael, which has already given a third shot of vaccine to <a href="https://datadashboard.health.gov.il/COVID-19/general?utm_source=go.gov.il&amp;utm_medium=referral">more than 45% of its people as of late December</a>, has seen a surge in cases driven by Omicron, although deaths have remained low. <div type="image" title="Charts show Israel's COVID-19 cases and deaths per million" height="1412" width="2000" msid="88974356" hostid="261"></div>"This graph of their Omicron wave isn't encouraging vs infections with 3rd booster," Eric Topol, director of the Scripps Research Translational Institute, <a href="https://twitter.com/EricTopol/status/1483299447865970691?s=20">tweeted Monday.</a>

You Searched For "booster dose" and got 7 results

No second Covid-19 booster dose required: Govt sources

ANI

Booster shots important says new study as Covid vaccine protection is short-lived

IANS

Serum Institute's Covovax gets DCGI approval as a heterologous booster dose

PTI

Indian genome scientists recommend COVID-19 booster dose for those above 40 years of age

PTI

Ideal time for COVID-19 booster shot is six months after the second dose, says Bharat Biotech MD

PTI

The new COVID-19 booster will be available at your local pharmacy by the end of the week

Grace Eliza Goodwin

Israeli vaccine study finds people still catching Omicron after 4 doses

Marianne Guenot

Popular Keywords

Buying Guides